Literature DB >> 10921719

Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR).

M García-Yuste1, J M Matilla, T Alvarez-Gago, J L Duque, F Heras, L J Cerezal, G Ramos.   

Abstract

BACKGROUND: This study examines the experience of the Spanish Multicenter Study of Neuroendocrine Tumors of the Lung through the clinical data and behavior of patients treated for this pathologic process.
METHODS: From 1980 to 1997, 361 cases of neuroendocrine carcinomas (NEC) were treated surgically. Patients were enrolled in a protocol using the pathologic and follow-up reports. According to Dreslers' criteria, the cases were segregated into grade 1 (typical carcinoid), grade 2 (atypical carcinoid), grade 3 large cell type, and grade 3 small cell type. Several variables were reviewed in all patients. Statistical analysis was performed to determine whether clinical characteristics and differentiation were associated with significant differences in the prognosis.
RESULTS: A total of 261 cases of NEC were identified with grade 1, 43 with grade 2, and with grade 3: 22 of large and 35 of small cells. Five-year survival for different grades was as follows: grade 1, 96%; 2, 72%; 3 large cell type, 21%; and 3 small cell type, 14%. When a comparative analysis between typical and atypical carcinoids was performed a significant difference for mean age, tumor size, nodal metastases, and recurrence was observed. However, female sex, nodal metastases, and recurrence rate differed between atypical carcinoids and grade 3 NEC of large cells. A difference in recurrence rate was found between patients with both types of grade 3 NEC.
CONCLUSIONS: The progressive deterioration of tumor organization highlights that neuroendocrine tumors constitute a continuous spectrum. A careful observation of pathologic findings is necessary to individualize their prognostic factors.

Entities:  

Mesh:

Year:  2000        PMID: 10921719     DOI: 10.1016/s0003-4975(00)01369-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  22 in total

1.  Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience.

Authors:  Ryan F Herde; Kristine E Kokeny; Chakravarthy B Reddy; Wallace L Akerley; Nan Hu; Jonathan P Boltax; Ying J Hitchcock
Journal:  Am J Clin Oncol       Date:  2018-01       Impact factor: 2.339

2.  Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumour.

Authors:  Miguel Angel Cañizares; Eva M García-Fontán; José Eduardo Rivo; Ana Gonzalez-Piñeiro
Journal:  Clin Transl Oncol       Date:  2005-06       Impact factor: 3.405

Review 3.  [Resection concepts for early stage neuroendocrine tumors of the lungs and bronchi].

Authors:  T Ploenes; C Aigner
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

4.  Atypical presentation of typical carcinoid.

Authors:  Karim El-Kersh; Umair Gauhar; Mohamed Saad
Journal:  BMJ Case Rep       Date:  2014-01-17

5.  Endobronchial Treatment for Bronchial Carcinoid: Patient Selection and Predictors of Outcome.

Authors:  Ellen M B P Reuling; Chris Dickhoff; Peter W Plaisier; Veerle M H Coupé; Albert H A Mazairac; Rutger J Lely; H Jaap Bonjer; Johannes M A Daniels
Journal:  Respiration       Date:  2018-02-12       Impact factor: 3.580

6.  Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

Authors:  Jarushka Naidoo; Maria L Santos-Zabala; Tunc Iyriboz; Kaitlin M Woo; Camelia S Sima; John J Fiore; Mark G Kris; Gregory J Riely; Piro Lito; Afsheen Iqbal; Stephen Veach; Stephanie Smith-Marrone; Inderpal S Sarkaria; Lee M Krug; Charles M Rudin; William D Travis; Natasha Rekhtman; Maria C Pietanza
Journal:  Clin Lung Cancer       Date:  2016-01-21       Impact factor: 4.785

7.  Large Cell Neuroendocrine Tumor Size >3 cm Negatively Impacts Long-Term Outcomes After R0 Resection.

Authors:  Maria Cattoni; Eric Vallières; Lisa M Brown; Amir A Sarkeshik; Stefano Margaritora; Alessandra Siciliani; Pier Luigi Filosso; Francesco Guerrera; Andrea Imperatori; Nicola Rotolo; Farhood Farjah; Grace Wandell; Kimberly Costas; Catherine Mann; Michal Hubka; Stephen Kaplan; Alexander S Farivar; Ralph W Aye; Brian E Louie
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

8.  Specific expression of ZO-1 and N-cadherin in rosette structures of various tumors: possible recapitulation of neural tube formation in embryogenesis and utility as a potentially novel immunohistochemical marker of rosette formation in pulmonary neuroendocrine tumors.

Authors:  Kaishi Satomi; Yukio Morishita; Shingo Sakashita; Yuzuru Kondou; Shuichiroh Furuya; Yuko Minami; Masayuki Noguchi
Journal:  Virchows Arch       Date:  2011-07-23       Impact factor: 4.064

Review 9.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

10.  Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung.

Authors:  Daisuke Okada; Masashi Kawamoto; Kiyoshi Koizumi; Shigeo Tanaka; Yuh Fukuda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.